Acclaim 3 – Genprex

Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

May 14, 2024Kalyn Dabbs Acclaim 3 Press Releases

Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Expects to Initiate the Phase 2 Expansion Study in the Second Half of 2024

Designed and Secured by Barsec

Copyright ©2024 all rights reserved.
Home - Privacy Policy - Terms of Use